Caldera launches with $112M, former Morphic CEO and IBD drug from China - Fierce Biotech

1/14/2026

A seasoned biotech VC looks to 2026 and sees a wave of IPOs coming - statnews.com

12/22/2025

Bruce Booth Has Seen It All in Biotech Venture Capital - WSJ

12/11/2025

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - BioSpace

11/18/2025

Drug developer Biogen unveils VC investment arm - Global Venturing

11/6/2025

Hemab collects another $157M to go after ‘underserved’ blood diseases - biopharmadive.com

10/27/2025

Atlas Venture Announces $400 Million Third Opportunity Fund - SynBioBeta

9/11/2025

Atlas Venture: $400 Million Opportunity Fund III Closed For Supporting Biotech Innovation - Pulse 2.0

9/8/2025

Atlas Venture closes on $400m Opportunity Fund III - venturecapitaljournal.com

9/5/2025

Atlas Venture Announces $400 Million Third Opportunity Fund - Business Wire

9/4/2025

Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound - statnews.com

9/4/2025

VC Atlas lands $400M to support existing biotech portfolio - Fierce Biotech

9/4/2025

Atlas' $400M growth fund will support its portfolio of biotechs - FirstWord Pharma

9/4/2025

Atlas Venture raises $400M to invest in later-stage biotechs - The Business Journals

9/4/2025

Renasant Bio launches to develop kidney disease treatment - C&EN

7/10/2025